According to the optimized protocol (Figure 1) introduced by the manufacturer (Biolynx, China), staining patterns on lung adenocarcinoma samples using the BP6165 concentrated antibody on the LYNX480 PLUS platform showed weaker specific cytoplasmic signals and less background than staining patterns with the ALK (D5F3) CDx Kit on the VENTANA BenchMark XT platform (Figure 2). This evidence concerns the gene ALK and lung adenocarcinoma.